Our compoundsResearch Pipeline

NRx Research Pipeline

Our pipeline includes medicinal candidates in Phase 2, and Phase 3 trials for COVID-19-related Lung Injury and Acute Respiratory Distress (ARDS), a next-generation vaccine platform against the Sars-CoV-2 virus, and the first drug in development to treat Bipolar Depression in Patients with Acute Suicidality.

 

COVID-19

Indication
Compound Name
Phase
Submission Type
Compound Type
Critical COVID-19 with
Respiratory Failure
Intravaneous ZYESAMI® (Avipdatil)
Phase 3
NDA
Drug

Study Sponsored by National Institute of Health | ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Status
Recruiting
Study Results
No Results Available
Locations
Duke University Hospital (Site 301-006), 2301 Erwin Road, Durham, North Carolina, United States | University of Utah Health (Site 211-002), 419 Wakara Way, Ste. 207, Salt Lake City, Utah, United States
Clinical Trial

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

Status
Completed
Study Results
No Results Available
Locations
Baptist Hospital of Miami, Miami, Florida, United States | Heartland/Mosaic Health, Saint Joseph, Missouri, United States | Hendrick Health, Abilene, Texas, United States | Houston Methodist Hospital, Houston, Texas, United States | Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States | St. Jude Medical Center, Fullerton, California, United States | Texas Health Harris Methodist Hospital, Fort Worth, Texas, United States | Texas Health Hospital Frisco, Frisco, Texas, United States | University of California – Irvine, Irvine, California, United States | University of Louisville Hospital, Louisville, Kentucky, United States
Clinical Trial
Critical COVID-19 with Respiratory Failure
Inhaled ZYESAMI® (Aviptadil Acetate)
Phase 2
NDA
Drug

Study Sponsored By The National Institute of Health | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (I-SPY_COVID)

Status
Recruiting
Study Results
No Results Available
Clinical Trial

Severe COVID-19
Inhaled ZYESAMI® (Aviptadil Acetate)
Phase 2/b/3
NDA
Drug

Inhaled ZYESAMI® (Aviptadil Acetate) for the Treatment of Moderate and Severe COVID-19

Status
Recruiting
Study Results
No Results Available
Locations
St. Jude Medical Center, Fullerton, California, United States | University of California – Irvine, Irvine, California, United States | University of Louisville Hospital, Louisville, Kentucky, United States
Clinical Trial

BriLife™ COVID 19 VACCINE

Indication
Compound Name
Phase
Submission Type
Compound Type
SARS-CoV-2
BriLife™
Phase 2/b/3
NDA
Drug

Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine. (BRILIFE002)

Status
Not yet recruiting
Study Results
No Results Available
Clinical Trial

BIPOLAR DEPRESSION | SUICIDAL IDEATION

Indication
Compound Name
Phase
Submission Type
Compound Type
Severe Bipolar Depression in patients
with Acute suicidal ideation
NRX-100/NRX-101™
Phase 2
NDA
Drug

Sequential Therapy for the Treatment of Severe Bipolar Depression.

Status
Completed
Study Results
No Results Available
Locations
Research Site, Birmingham, Birmingham, Alabama, United States | Research Site, Charlotte, Charlotte, North Carolina, United States | Research Site, Houston, Houston, Texas, United States
Clinical Trial
Severe Bipolar Depression in patients
with Acute suicidal ideation
NRX-101™
Phase 2/b/3
NDA
Drug

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Status
Recruiting
Study Results
No Results Available
Locations
JP Smith Hospital, Fort Worth, Texas, United States | Research Centers of America, Hollywood, Florida, United States | Research Site, Birmingham, Birmingham, Alabama, United States | Research Site, Houston, Houston, Texas, United States | Texas Health Hospital Frisco, Frisco, Texas, United States | University of California – Irvine, Irvine, California, United States | University of Louisville Hospital, Louisville, Kentucky, United States | University of Utah Health (Site 211-002), 419 Wakara Way, Ste. 207, Salt Lake City, Utah, United States
Clinical Trial
Acute Suicidality Ideation and Behavior
(ASIB) in Bipolar Depression
NRX-100™
Phase 3
NDA
Drug

NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression

Status
Recruiting
Study Results
No Results Available
Locations
JP Smith Hospital, Fort Worth, Texas, United States | Research Centers of America, Hollywood, Florida, United States
Clinical Trial
Moderate Bipolar Depression with
Suicidal Ideation
NRX-101™
Phase 2/3
NDA
Drug

NRX101 for Moderate Bipolar Depression and Suicidal Ideation

Status
Not yet recruiting
Study Results
No Results Available
Clinical Trial